A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Epistemonikos ID: 94a84bd746cb8887f763380d2894be33598e1ed6
First added on: May 07, 2024